About: Antibody Detection and Dynamic Characteristics in Patients with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antibody Detection and Dynamic Characteristics in Patients with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antibody Detection and Dynamic Characteristics in Patients with COVID-19
Creator	Li, Hui Cai, Pengcheng Ye, Hong Zhang, Jianchu Xiang, Fei Ma, Wan-Li Ma, Yanling Wang, Xiaorong Yang, Bohan Zhou, Qiong Wei, Xiaoshan He, Xinliang Peng, Zhenghong
Source	Medline; PMC
abstract	BACKGROUND: The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed. METHODS: The antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate. RESULTS: The seroconversion of specific IgM and IgG antibodies were observed as early as the 4(th) day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity. CONCLUSIONS: The antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.
has issue date	2020-04-19(xsd:dateTime)
bibo:doi	10.1093/cid/ciaa461
bibo:pmid	32306047
has license	no-cc
sha1sum (hex)	037a88db28e5bd297aa991adc67fed595c4f197d
schema:url	https://doi.org/10.1093/cid/ciaa461
resource representing a document's title	Antibody Detection and Dynamic Characteristics in Patients with COVID-19
has PubMed Central identifier	PMC7188146
has PubMed identifier	32306047
schema:publication	Clin Infect Dis
resource representing a document's body	covid:037a88db28e5bd297aa991adc67fed595c4f197d#body_text
is schema:about of	named entity 'nationwide' named entity 'Patients' named entity 'rapidly' named entity 'SARS-CoV-2' named entity 'Antibody' named entity 'pneumonia' named entity 'COVID' named entity 'sensitivity, specificity' named entity 'IgM' named entity 'IgM antibody' named entity 'pneumonia' named entity 'epidemiological' named entity 'lung disorders' named entity '450 nm' named entity 'public health' named entity 'SARS-CoV-2' named entity 'RT-PCR' named entity 'COVID' named entity 'IgG' named entity 'RT-PCR test' named entity 'infection' named entity 'outbreak investigation' named entity 'serum' named entity 'pneumonia' named entity 'nucleic acid detection' named entity 'pneumonia' named entity 'lung cancer' named entity 'pneumonia' named entity 'antibodies' named entity 'P.R.China' named entity 'Comorbidities' named entity 'symptom' named entity 'Oxygen' named entity 'IgM' named entity 'log-normal distribution' named entity 'IgG antibody' named entity 'immune responses' named entity 'fever' named entity 'PPV' named entity 'IgM' named entity 'IgG antibodies' named entity 'IgM' named entity 'sample size' named entity 'pneumonia' named entity 'COVID-19' named entity 'optical density' named entity 'microplate reader' named entity 'Log-normal distribution' named entity 'cell lysates' named entity 'RT-PCR' named entity 'RT-PCR' named entity 'IgM' named entity 'Arterial partial pressure of oxygen' named entity 'COVID-19' named entity 'IgG antibody' named entity 'IgM' named entity 'IgM' named entity 'PPV' named entity 'lymphocytes' named entity 'emerging infection' named entity 'RT-PCR' named entity 'COVID' named entity 'nucleic acid tests' named entity 'surgical operation' named entity 'IgG antibody' named entity 'blood donors' named entity 'corona virus' named entity 'COVID' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software